Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.

Amgen Inc. (AMGN) is a leading biotechnology company headquartered in Thousand Oaks, California. It specializes in the ...

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the ...

Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings this Tuesday after the bell. Here’s what to look for. Amgen ...

On January 26, UBS lifted its price target on Amgen Inc. (NASDAQ:AMGN) to $390 from $380 and kept a Buy rating on the stock.

Amgen’s AMGN stock has risen almost 16% in a month. A lot of this price increase is due to strong third-quarter 2025 results, wherein both the top and bottom lines exceeded expectations. Amgen also ...

Amgen's weight management candidate looks very promising. The large biotech boasts a deep pipeline beyond that segment. Amgen's dividend looks great, and the stock is reasonably valued. Even so, there ...

Amgen says its MariTide obesity drug helped patients maintain weight loss for a second year, with good safety and fewer side effects.

Amgen Inc. Buy thesis: strong pipeline, 12% Q3 2025 revenue growth and MariTide obesity upside. Click for this updated look ...